Search

Found 345 Results
Page 1 of 35

Onxeo reports its financial results for the first half of 2020 and provides an update on its activities


The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]

09/17/2020


Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020


Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

09/08/2020


HealthTech Innovation Days – France Biotech


October 5-6, 2020 in Paris, France (virtual conference) This event includes conferences and meetings between innovative European companies in the […]

09/07/2020


Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States


This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

Tags:

09/03/2020


Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer


DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

Tags:

08/27/2020


Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility


Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

07/29/2020


H.C. Wainwright 22nd Annual Global Investment Conference


September 14-16, 2020 (virtual conference) Onxeo’s management team will present the Company on September 15 at 1:00 pm EDT (19:00 […]

07/28/2020


Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux


July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

Tags:

07/03/2020


Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties


Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

06/25/2020


New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020


Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

Tags:

06/22/2020


Page 1 of 35

No more results